Clinical TrialsThe completion of the database lock for the Phase 2 BMT-801 trial evaluating bremelanotide with tirzepatide for obesity is expected to provide critical data for Palatin as it shifts its focus to the obesity space.

Strategic FocusPalatin's strategic focus has shifted primarily to its obesity program, which management views as the primary driver of long-term success.

ValuationThe valuation of Palatin's stock appears attractive based on the initial addressable market size, supporting the Buy rating and price target.

Bears Say

Clinical Trial ChallengesPalatin may need to achieve more than 7–8% weight loss from baseline with a comparable or better safety profile using its combination approach to achieve positive investor sentiment.

Financial StatusThe company ended the quarter with $3.4 million in cash, which does not include a recent equity raise of $4.3 million this month.

Funding NeedsFactors that could impede reaching the price target include failed or inconclusive clinical trials or the inability to secure adequate funding for drug development.

Options Prices

Currently, No data available

---

Ownership Overview

1.85%

Insiders

1.63%

Mutual Funds

6.10% Other Institutional Investors

89.18% Public Companies and Individual Investors

Detailed Ownership Overview >

PTNT FAQ

What was Palatin Technologies, Inc.’s price range in the past 12 months?

Palatin Technologies, Inc. lowest stock price was $0.04 and its highest was $1.98 in the past 12 months.

What is Palatin Technologies, Inc.’s market cap?

Palatin Technologies, Inc.’s market cap is $6.97M.

When is Palatin Technologies, Inc.’s upcoming earnings report date?

Palatin Technologies, Inc.’s upcoming earnings report date is Oct 07, 2025 which is in 101 days.

How were Palatin Technologies, Inc.’s earnings last quarter?

Palatin Technologies, Inc. released its earnings results on May 14, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.01.

Is Palatin Technologies, Inc. overvalued?

According to Wall Street analysts Palatin Technologies, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palatin Technologies, Inc. pay dividends?

Palatin Technologies, Inc. does not currently pay dividends.

What is Palatin Technologies, Inc.’s EPS estimate?

Palatin Technologies, Inc.’s EPS estimate is -0.19.

How many shares outstanding does Palatin Technologies, Inc. have?

Palatin Technologies, Inc. has 46,479,862 shares outstanding.

What happened to Palatin Technologies, Inc.’s price movement after its last earnings report?

Palatin Technologies, Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went up 11.111%.

Which hedge fund is a major shareholder of Palatin Technologies, Inc.?

Currently, no hedge funds are holding shares in PTNT

Company Description

Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on developing targeted receptor-specific therapeutics for the treatment of various medical conditions. The company primarily operates in the biotechnology sector, with a strong emphasis on developing treatments for inflammatory diseases and disorders related to sexual dysfunction. Palatin's core product includes Vyleesi, a melanocortin receptor agonist indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).

PTNT Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mixed view with significant achievements in reducing net loss and promising clinical trial results. However, challenges remain with the absence of product sales and a decrease in cash position. The company is actively pursuing strategic partnerships to enhance its future prospects.Read More>